Xortx Gets Orphan Drug Nod for Polycystic Kidney Disease

Xortx Therapeutics has received Orphan Drug designation for its Xorlo (oxypurinol) drug to treat autosomal dominant polycystic kidney disease, the most common form of polycystic kidney disease.

Xorlo inhibits the production of uric acid, a key to reducing injury to the kidney.

The company plans on speaking with the FDA on May 1 about its planned phase 3 clinical program of the drug candidate.

Orphan Drug designation offers incentives for companies such as a possible tax credit of 25 percent of qualified clinical drug testing costs upon drug approval.

Related Topics